Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

scientific article

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2014-04-567164
P932PMC publication ID4141519
P698PubMed publication ID24982504
P5875ResearchGate publication ID263585014

P50authorEdmund K WallerQ59682183
Joseph H AntinQ89778009
Margaret L MacMillanQ93064323
Stephan A GruppQ104495066
David L. PorterQ110797660
Laura J. JohnstonQ116194191
P2093author name stringMarcelo Pasquini
Philip McCarthy
Corey Cutler
Juan Wu
Jack W Hsu
Zhen-Huan Hu
Brent Logan
Mary M Horowitz
Ryotaro Nakamura
Sung Choi
William J Hogan
Shelly L Carter
P2860cites workAllogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trialsQ30997153
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantationQ33366979
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimensQ33387336
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisQ33403897
Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study GroupQ33862023
Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantationQ34249446
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Q34451427
Reduced mortality after allogeneic hematopoietic-cell transplantationQ34472861
Cytokine dysregulation and acute graft-versus-host diseaseQ35607602
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantationQ35750957
Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantationQ35845541
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemiaQ35953348
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisQ36206849
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationQ36662042
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantationQ37001941
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).Q37169115
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantationQ37247581
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Q37670062
Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysisQ38178000
1994 Consensus Conference on Acute GVHD GradingQ39513397
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.Q42552189
Prediction of veno-occlusive disease using biomarkers of endothelial injuryQ42737854
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxisQ43183770
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantationQ43790464
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemiaQ44237334
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimensQ46450537
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.Q54684597
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host diseaseQ68882743
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trialQ73933735
Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory boardQ74664011
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantationQ78410438
P433issue8
P407language of work or nameEnglishQ1860
P1104number of pages6
P304page(s)1372-1377
P577publication date2014-06-30
P1433published inBloodQ885070
P1476titleTacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
P478volume124